⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CSTL News
Castle Biosciences, Inc. Common Stock
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
globenewswire.com
CSTL
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
globenewswire.com
CSTL
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
globenewswire.com
CSTL
SciBase receives initial order for clinical study from Castle Biosciences
prnewswire.com
CSTL